Clearpoint Neuro (CLPT) investor relations material

Executive summary

• Achieved record Q1 2026 revenue of $12.1 million, up 43% year-over-year, driven by organic device growth, IRRAflow acquisition, and neurosurgery navigation and therapy sales.

• Integration of IRRAS Holdings, Inc. expanded the product portfolio into neurocritical care, contributed to revenue and cost synergies, and broadened global reach.

• Net loss widened to $9.6 million from $6.0 million in Q1 2025, reflecting higher operating expenses and interest costs.

• Over 60 active biopharma partners, 25+ clinical trials, and 10+ programs under FDA expedited review, with first commercial drug delivery in Asia-Pacific.

• FDA clearance and first clinical use of the Velocity Alpha MR High Speed Surgical Drill System.

Financial highlights

• Q1 2026 revenue: $12.1 million vs. $8.5 million in Q1 2025 (43% growth; 16% organic).

• Neurosurgery navigation, therapy, and access revenue reached $5.9 million, including IRRAflow and new software launches.

• Capital equipment and software revenue rose 177% to $1.4 million year-over-year.

• Gross margin improved to 64% from 60% in Q1 2025, mainly due to lower inventory reserves.

• Cash and equivalents at $35.6 million as of March 31, 2026, down from $45.9 million at year-end 2025, mainly due to $8 million operational cash burn and $2 million in tax payments.

• Net loss per share: $(0.32) vs. $(0.22) year-over-year; weighted average shares outstanding: 29.5 million.

Outlook and guidance

• 2026 revenue expected in the range of $52 million–$56 million.

• All four business segments projected to grow double digits in 2026.

• Operational cash burn expected to decrease as IRRAS integration completes, with potential for cash neutrality by 2027.

• Sequential quarter-over-quarter revenue growth anticipated for the remainder of 2026.

• Cash balances projected to support operations for at least the next twelve months.